Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) for the reporting period ending April 30, 2010. The filing reports the closing of a financing tranche under a previously amended Securities Purchase Agreement with 10X Fund, L.P.
Key Financial Metrics
- Gross Proceeds: $310,000
- Net Proceeds: Approximately $297,000 (after reimbursement of purchaser expenses and a 3% origination fee)
- Securities Issued:
- 155,000 shares of Series B-2 Preferred Stock (convertible into 620,000 shares of Common Stock)
- Class A-1 Warrants (exercisable for 310,000 shares of Common Stock)
- Class A-2 Warrants (exercisable for 310,000 shares of Common Stock)
- Class B Warrants (exercisable for 1,240,000 shares of Common Stock)
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, or operating cash flow.
- Debt/Liquidity: The filing does not provide a clear value for total debt or overall liquidity position, other than the specific proceeds from this transaction.
Material Changes
The primary material change is the issuance of new equity and warrant securities to 10X Fund, L.P. on April 30, 2010, pursuant to the Amended Purchase Agreement dated August 11, 2009. This represents a new tranche of funding under the existing facility.
Outlook, Risks, and Contingencies
- Redemption Obligation: Holders of Series B-2 Preferred Stock may require the Company to redeem shares in whole or in part at any time on or after two years from the date of issuance (post-April 30, 2012). The redemption price includes the stated value plus accrued but unpaid dividends.
- Default Contingency: If the Company fails to pay the redemption price in cash on the redemption date, holders may automatically convert their shares into a promissory note bearing interest at 15% per year, secured by a lien on all assets of the Company.
- Regulatory Status: The securities were issued as unregistered "restricted securities" in reliance on Section 4(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the total outstanding amount of Series B-1 and Series B-2 Preferred Stock to assess potential future redemption liabilities.
- Confirm the current cash balance and burn rate to evaluate the ability to meet the 15% interest-bearing note contingency if a redemption event occurs.
- Review the full text of the warrant agreements (Exhibits 4.1, 4.2, 4.3) to understand exercise prices and expiration dates, which are not detailed in this summary.
- Check subsequent filings for any additional tranches issued under the Amended Purchase Agreement.